https://www.investorvillage.com/smbd.asp?mb=1086&mn=1752…
Take a look at cabo/nivo data in previously treated rcc patients.
Among the 13 patients with mRCC who were evaluable for response, ORR was 54 percent (7 PRs of 13 patients) and the DCR was 100 percent.
No treatment naive patients in rcc cohort.
214 is obviously active, but I wonder if bmy is betting on the safety profile of 214 will make it a winner. 214 comparable in efficacy, but early data doesn’t appear superior to other drug combos.
We’ll see when data matures to the point we can actually get long term OS and pfs data. Then we can really compare it to other drug combinations.